Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. (Nasdaq: ARTL) on April 8, 2021, covering events occurring on April 8 and April 9, 2021. The Company is a Nevada corporation focused on advancing product candidates through research, development, and clinical studies.
Key Financial Metrics and Agreements
This filing does not contain audited financial statements, revenue, profit, or cash flow data. The primary financial event reported is the entry into a new capital raising mechanism:
- At Market Issuance Sales Agreement: Entered into on April 9, 2021, with Ladenburg Thalmann & Co. Inc.
- Offering Size: Up to $20,500,000 in aggregate offering price of common stock.
- Commission: 3.0% of aggregate gross proceeds paid to Ladenburg.
- Use of Proceeds: General corporate purposes, including manufacturing, R&D, clinical studies, capital expenditures, and working capital.
Material Changes Versus Prior Period
The filing reports a material change in the Company's equity distribution strategy:
- Termination of Prior Agreement: The Company terminated its Equity Distribution Agreement with Maxim Group, LLC, effective April 8, 2021.
- New Arrangement: Immediately following the termination, the Company executed a new At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to replace the previous arrangement.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use net proceeds from the new agreement to advance its product candidates. The Company is not obligated to sell any shares under the new agreement.
Risks and Contingencies:
- The agreement may be terminated by either party upon ten days' prior notice.
- Ladenburg may terminate the agreement in certain circumstances, including the occurrence of a material adverse effect on the Company.
- Sales are subject to market conditions and the Company's instructions regarding price, time, and size limits.
Investor Verification Checklist
- Verify the current market price of ARTL common stock to assess the potential dilution impact of a $20.5 million offering.
- Review the Company's most recent 10-K or 10-Q filings for actual cash balances and burn rate to determine the urgency of the capital raise.
- Confirm the status of the prospectus supplement referenced in the filing, as sales cannot commence until it is filed.
- Monitor future 8-K filings for actual sales volumes and proceeds generated under the new Ladenburg agreement.